You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Novel therapies for inherited muscle diseases

    SBC: Medosome Biotec, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. High speed Intraoperative Assessment of Breast Tumor Margin using MarginPAT

    SBC: Vibronix, Inc.            Topic: O

    After a breast conserving therapy histology is often performed to check whether the excised tumor specimen is surrounded by a sufficient amount of normal tissue If a positive margin is identified then a second operation will be performed Currently the re operation rate is which raises a need for intraoperative detection of residual cancers The current intraoperative tools for margin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of peptide inhibitors for neuroinflammation and neurodegeneration

    SBC: PROVAIDYA            Topic: NIA

    DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Optimized AAV Serotype Vectors for Human Gene Therapy

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Developing novel RPPA for the detection of metastatic prostate cancer

    SBC: Tymora Analytical Operations, LLC            Topic: 102

    PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 103

    ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government